← All Altimmune, INC filings

Altimmune, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ALT
Altimmune, INC
10-K: Altimmune's Pemvidutide Shines in MASH, Expands Pipeline
Altimmune reports strong Phase 2b MASH results for pemvidutide, secures FDA designations, and advances trials for AUD and ALD, signaling significant pipeline progress.
NASDAQ
ALT
Altimmune, INC
10-K: Altimmune's 2024 10-K Filing: Pemvidutide Advances to Phase 3 Trials for Obesity, MASH Program Continues
Altimmune reports its 2024 financial results and provides an update on its clinical programs, highlighting the advancement of pemvidutide to Phase 3 trials for obesity and ongoing Phase 2b trial for MASH.
NASDAQ
ALT
Altimmune, INC
10-K: Altimmune Details Share Structure and Regulatory Framework in 10-K Filing
Altimmune's 10-K filing outlines the company's share structure, voting rights, dividend policies, and regulatory framework, including details on common and preferred stock, warrants, and anti-takeover provisions.